Why Everyone Is Wrong About Coca-Cola's Defensive Premium

The bull case writes itself. Coca-Cola owns the world's most recognised brand. The franchise model means the company doesn't actually make or distribute most of its product — bottling partners bear those costs and risks. Revenue of $47.1 billion generates $12.5 billion in net income at a 26.5% profit margin and $12.1 billion in free cash flow. The balance sheet carries $18.3 billion in debt, but debt service is comfortable at 4x interest coverage.

Investors pay 26x for this because they believe the cash flows are as close to permanent as any business can offer. In a world of geopolitical uncertainty, AI disruption, and tariff chaos, Coca-Cola feels like solid ground.

We get the appeal. But solid ground and good investment are two different things.

Here's the arithmetic the bulls don't want to run. Coca-Cola is guiding for 4-5% organic revenue growth and 7-8% EPS growth (including buybacks) for 2026. At 26x forward earnings, the stock is priced to deliver approximately 10-11% total return including the dividend. That's fine.

But that return requires the multiple to hold. And this is where the bull case gets fragile. If the multiple compresses from 26x to 22x — still generous by any absolute standard — the stock drops 15% even with perfect execution. Multiple compression from 26x to 20x, which is where KO traded as recently as 2019, implies 23% downside.

The risk-reward is asymmetric in the wrong direction. Upside requires multiple expansion or earnings acceleration. Neither is plausible. Downside requires only a modest re-rating to historical averages.

The consensus has been wrong before on defensive names — they can stay expensive for painfully long periods. But at some point, the gap between growth rate and valuation multiple becomes untenable. We think KO is approaching that point.

Here's the catalyst that could accelerate the re-rating. GLP-1 weight loss drugs — Ozempic, Wegovy, Mounjaro — are reducing caloric intake across a growing portion of the US and European populations. Early data suggests GLP-1 users reduce sugary beverage consumption by 30-40%.

The current GLP-1 user base is relatively small — approximately 6 million in the US. But adoption is accelerating. If penetration reaches 15-20 million by 2028, as several forecasts suggest, the impact on carbonated soft drink volumes becomes material.

Coca-Cola has been pivoting toward zero-sugar variants and non-carbonated beverages, but the core brand remains a full-sugar carbonated drink. The GLP-1 threat isn't priced into the multiple because the volume impact hasn't shown up in quarterly results yet. But the structural shift in consumer health behaviour is unmistakable.

This reminds us of the early days of the anti-tobacco movement. The impact on cigarette volumes took years to become visible in the numbers, but by the time it was, the multiple compression had already happened. The smart money moved early.